GSK appoints Luke Miels as CEO designate, set to lead the company into a pivotal growth phase starting January 2026.

The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a post-pandemic world.

Genmab's acquisition of Merus for $8 billion enhances its oncology portfolio, promising growth and innovative therapies like Petosemtamab for cancer treatment.

The FDA has expanded Johnson & Johnson’s Tremfya (guselkumab) approval to children six years and older weighing at least 40 kilograms with moderate to severe plaque psoriasis or active psoriatic ...

In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels as its next CEO, and the FDA’s approval of ...

AbbVie is investing over $10 billion in U.S. manufacturing, focusing on immunology, oncology, and neuroscience medicines. The new North Chicago facility will shift some manufacturing from Europe and ...

The MFN order could alter pharmaceutical innovation by enforcing foreign price-based drug cost reductions in the U.S. The biopharma industry, comprising investors and companies, may struggle with U.S.

AstraZeneca aims to harmonize its share listings globally to enhance sustainable growth and investor reach, maintaining headquarters in the UK. Enhertu shows superior outcomes in early-stage ...